Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events

OBJECTIVE: To examine the comparative effectiveness of the sodium–glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin and other non-SGLT2i antihyperglycemics on the risk of major adverse kidney events (MAKE) of estimated glomerular filtration rate (eGFR) decline >50%, end-stage kidney diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yan, Bowe, Benjamin, Gibson, Andrew K., McGill, Janet B., Yan, Yan, Maddukuri, Geetha, Al-Aly, Ziyad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2020
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576413/
https://www.ncbi.nlm.nih.gov/pubmed/32912850
http://dx.doi.org/10.2337/dc20-1231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576413/
https://www.ncbi.nlm.nih.gov/pubmed/32912850
http://dx.doi.org/10.2337/dc20-1231

Ejemplares similares